Bolt Biotherapeutics, Inc. (BOLT)
6.27
+2.08
(+49.64%)
USD |
NASDAQ |
Oct 23, 16:00
6.85
+0.58
(+9.25%)
After-Hours: 20:00
Bolt Biotherapeutics Profit Margin (Quarterly) : -154.4K% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -154.4K% |
| March 31, 2026 | -27.86K% |
| December 31, 2025 | -265.2% |
| September 30, 2025 | -329.4% |
| June 30, 2025 | -474.6% |
| March 31, 2025 | -903.4% |
| December 31, 2024 | |
| September 30, 2024 | -1.33K% |
| June 30, 2024 | -1.66K% |
| March 31, 2024 | -205.0% |
| December 31, 2023 | -857.0% |
| September 30, 2023 | -643.1% |
| June 30, 2023 | -1.26K% |
| March 31, 2023 | -929.9% |
| Date | Value |
|---|---|
| December 31, 2022 | -1.42K% |
| September 30, 2022 | -1.03K% |
| June 30, 2022 | -1.63K% |
| March 31, 2022 | -2.91K% |
| December 31, 2021 | -5.35K% |
| September 30, 2021 | -3.11K% |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | -16.51K% |
| March 31, 2020 | -5.26K% |
| December 31, 2019 | -14.40K% |
| September 30, 2019 | -5.94K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -237.8% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | -2.15K% |
| Sarepta Therapeutics, Inc. | -1.22% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -110.6% |
| Return on Assets | -49.32% |
| Return on Invested Capital | -58.75% |
| Gross Profit Margin (Quarterly) | -3.32K% |
| Operating Margin (Quarterly) | -151.3K% |
| Return on Net Operating Assets | -140.5% |